ArticleJournal of nanobiotechnology2026
Selenium‑based nanotherapeutics promote healing of infected diabetic wounds via photothermal‑driven macrophage immunometabolic reprogramming and the NRF2/HIF‑1α axis.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Innovative microneedle-integrated hydrogels: a promising strategy for diabetic foot ulcer management.Frontiers in bioengineering and biotechnology · 2026Review
- From Bioactive Selenium Nanoparticles to Multifunctional Dermatological Platforms: Mechanism-Guided Design and Translational Challenges.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Infected wounds heal considerably slowly among patients with diabetes because of biofilm barriers and immune dysregulation. Therefore, treatment strategies must simultaneously eliminate infection and accelerate healing. In this study, we present a dual-mechanism nanoplatform composed of indocyanine green (ICG)-loaded lentinan (LNT)‑functionalized selenium nanoparticles (ICG@LNT‑SeNPs). This platform disrupts the pathological cycle by integrating near‑infrared‑triggered photothermal eradication of methicillin-resistant Staphylococcus aureus (MRSA) biofilms with selenium‑driven immunometabolic reprogramming of macrophages. The selenium (Se) component facilitates metabolic adaptation and functional remodeling of pro‑inflammatory macrophages by activating the NRF2/HIF‑1α axis, inducing transition into an M2 phenotype, which is characterized by elevated expression of repair‑associated factors (e.g., Il10 and Arg1). ICG@LNT‑SeNPs also enhance the defensive properties of cellular antioxidants by upregulating the expression of Secisbp2 (a key regulator of selenoprotein biosynthesis), Gpx4, and Txnrd2. This combined antibacterial‑metabolic‑immune mechanism causes vascular endothelial cells and fibroblasts to migrate, enhancing subsequent collagen deposition and angiogenesis and, thus, accelerating wound closure. This mechanism demonstrated more mature tissue reconstruction in diabetic mice with MRSA-infected wounds. Overall, the proposed SeNPs-based therapeutic strategy promotes infected diabetic wounds healing through macrophage immunometabolic reprogramming. The findings may help identify new targets and provide insights for developing promising management approaches for chronic wounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.